MedCan.se

En patientförening som samlar alla som behöver medicinsk cb!

[MedCan.se @MedCanSe]

Extempore-förskrivning ökar kraftigt. Alltså specialanpassade blandningar av örten utöver godkända läkemedel, som i Sverige är Sativex och Epidyolex.
https://t.co/kUtTAZXV7J

[MedCan.se @MedCanSe]

Myndigheten TLV meddelade igår att Epidyolex subventioneras vid svår epilepsi – viktigt steg för patienter i Sverige. https://t.co/iFzPAjakSh

[MedCan.se @MedCanSe]

Ny brittisk undersökning: patienter rapporterar förbättrad sömn, vardagsfunktion och symtom efter medicinskt bruk på recept. https://t.co/PtpPZnqBX8

[MedCan.se @MedCanSe]

För växtdelar dvs blomma är det på tok för lite:
"Förra året ansökte 133 personer om licensförskrivning och 81 beviljades."

[MedCan.se @MedCanSe]

"Aldrig tidigare har så många svenskar fått cannabis utskrivet av vården.
På tio år har antalet patienter nästan 20-dubblats, men jämfört med många andra länder är förskrivningen fortfarande låg."
https://t.co/EqGxY1e2Cz

[MedCan.se @MedCanSe]

Se video:
https://t.co/n7kJml2JRg

[MedCan.se @MedCanSe]

Bra att stormedia börjar ta upp det här med risk för indraget högkostnadsskydd gällande medicinska APL-oljor!
https://t.co/Vp8xfly9al

[MedCan.se @MedCanSe]

Skriv under namninsamlingen för att stoppa myndigheten TLV!
https://t.co/Q4jPDDbcAa

[MedCan.se @MedCanSe]

Intressant om patienter som använder medicinsk cb och kör bil! Ingen signifikant påverkan på körförmågan enligt studie.

[Cannabis.se @CannabisSE]

Kan du köra bil efter att ha använt ett naturligt växtbaserade läkemedel?
En ny australisk studie visar att patienter som använder förskriven örtmedicin i inhalerad form inte kör sämre – men de känner sig mindre säkra bakom ratten.

[MedCan.se @MedCanSe]

Skriv under här:
https://t.co/Q4jPDDbcAa

[MedCan.se @MedCanSe]

Har du skrivit under namninsamlingen för att protestera mot TLV, myndigheten som vill dra in högkostnadsskyddet för medicinska oljor? ✊🖊🔥🥦

[MedCan.se @MedCanSe]

Igår lanserades MedCan officiellt under hampafestivalen. Väktarna och polisen vill först gripa en av föreningens styrelseledamöter då de hävdade att det inte finns något som heter medicinsk cb i Sverige!

[Medicinsk Cannabis i Sverige @MCiSverige]

Enligt forskare vid @karolinskainst: ”Cannabis-studier har påfallande ofta låg kvalitet, problem med öppenhet med data – och det finns inget vetenskapligt stöd för att cannabis skulle ha mer än placeboeffekter på långvarig smärta.” [1]

Men stämmer det? Nej.

Döm själv👇

Fakta > fördomar.

[1] https://t.co/imL5RsrYuV

@karolinskainst @FilipGedin @Aftonbladet @dagensmedicin @SvDledare @svtnyheter @DNDebatt @dagensnyheter @Expressen @ExpressenLedare @TidningenSyre @Drug_News @Nyheterna

Reechaye et al., Cureus, 2024.
Cannabinoids as a Natural Alternative for the Management of Neuropathic Pain: A Systematic Review of Randomized Placebo-Controlled Trials
Compared to placebo, cannabinoids provided significant relief from chronic pain (33% vs 15%) as measured by the visual analog scale. https://t.co/CTXFQSo8x2

Jeddi et al., BMJ Open, 2024
Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised clinical trials.
Moderate certainty evidence showed that opioids provide small improvements in pain, physical functioning and sleep quality versus placebo; low to moderate certainty evidence supported similar effects for cannabis versus placebo. https://t.co/OcB3i8Dio4

Barakji., PLoS One, 2023
Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis
Meta-analyses and Trial Sequential Analysis showed that cannabinoids reduced chronic pain (mean difference NRS -0.43; 98% CI -0.72 to -0.15; P = 0.0004) and improved quality of sleep (mean difference -0.42; 95% CI -0.65 to -0.20; P = 0.0003).
https://t.co/T51LyQ7jhE

Häuser et al., Cochrane, 2023
Cannabis-based medicines and medical cannabis for adults with cancer pain
There was low-certainty evidence that synthetic THC analogues were superior to placebo (SMD -0.98, 95% CI -1.36 to -0.60), but not superior to low-dose codeine (SMD 0.03, 95% CI -0.25 to 0.32; 5 single-dose trials; 126 participants) in reducing moderate-to-severe cancer pain after cessation of previous analgesic treatment for three to four and a half hours (2 single-dose trials; 66 participants).
https://t.co/mR0ws6PnUz

Solmi et al., BMJ, 2023
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.
For chronic pain, cannabis based medicines or cannabinoids reduced pain by 30% (0.59 (0.37 to 0.93), GRADE=high), across different conditions (n=7), but increased psychological distress.
https://t.co/QCMhQwEcKV

McDonagh et al., Ann Intern Med., 2022
Cannabis-Based Products for Chronic Pain : A Systematic Review
Synthetic products with high THC-to-CBD ratios (>98% THC) may be associated with moderate improvement in pain severity and response (≥30% improvement) and an increased risk for sedation and are probably associated with a large increased risk for dizziness. Extracted products with high THC-to-CBD ratios (range, 3:1 to 47:1) may be associated with large increased risk for study withdrawal due to adverse events and dizziness.
https://t.co/tpHOj60Z5m

Giossi et al., Pain Ther., 2022
Systematic Review and Meta-analysis Seem to Indicate that Cannabinoids for Chronic Primary Pain Treatment Have Limited Benefit
VAS pain reduction was non-significant for cannabinoids against placebo (MD = - 0.64; 95% CI - 1.30 to 0.02) or amitriptyline (MD = - 0.19; 95% CI - 0.58 to 0.19). More than 4 weeks cannabinoid treatment significantly reduced pain compared to placebo in parallel studies with more than 4 weeks of treatment duration (MD = - 1.28; 95% CI - 2.33 to - 0.22).
https://t.co/HXhEDKgJDe

Bialas et al., Eur J Pain., 2022
Long-term observational studies with cannabis-based medicines for chronic non-cancer pain: A systematic review and meta-analysis of effectiveness and safety
The weighted mean difference of mean pain reduction was 1.75 (95% confidence interval [CI] 0.72 to 2.78) on a 0-10 scale. 20.8% (95% CI 10.2% to 34.0%) of patients reported pain relief of 50% or greater.
https://t.co/v0tcWW1QaW

Fisher et al., PAIN., 2021
Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials
Evidence of benefit was found for cannabis <7 days (risk difference 0.33, 95% confidence interval 0.20-0.46; 2 trials, 231 patients, very low-quality evidence) and nabiximols >7 days (risk difference 0.06, 95% confidence interval 0.01-0.12; 6 trials, 1484 patients, very low-quality evidence).
https://t.co/bHQBZrON5k

Longo et al., Pain Manag Nurs., 2021
Cannabis for Chronic Pain: A Rapid Systematic Review of Randomized Control Trials
Thirteen randomized controlled trials met the inclusion criteria. Five demonstrated moderate analgesic effects of cannabis for chronic pain, and eight concluded there were no significant impacts on pain in the cannabis-treated group versus the control group.
https://t.co/7q07vGdBlq

Wang et al., BMJ., 2021
Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials
Compared with placebo, non-inhaled medical cannabis probably results in a small increase in the proportion of patients experiencing at least the minimally important difference (MID) of 1 cm (on a 10 cm visual analogue scale (VAS)) in pain relief (modelled risk difference (RD) of 10% (95% confidence interval 5% to 15%), based on a weighted mean difference (WMD) of -0.50 cm (95% CI -0.75 to -0.25 cm, moderate certainty)).
https://t.co/VPzi5y57jX

Sainsbury et al., Review J Dent Anesth Pain Med., 2021
Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis
Meta-analysis showed that there was a significant reduction in pain intensity for THC/CBD by -6.624 units (P < .001), THC by -8.681 units (P < .001), and dronabinol by -6.0 units (P = .008) compared to placebo on a 0-100 scale. CBD, CBDV, and CT-3 showed no significant differences. Patients taking THC/CBD were 1.756 times more likely to achieve a 30% reduction in pain (P = .008) and 1.422 times more likely to achieve a 50% reduction (P = .37) than placebo. Patients receiving THC had a 21% higher improvement in pain intensity (P = .005) and were 1.855 times more likely to achieve a 30% reduction in pain than placebo (P < .001).
https://t.co/wFKZf9cSkq

Rabgay et al., J Am Pharm Assoc., 2020
The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis
We found that delta-9-tetrahydrocannabinol/cannabidiol (THC/CBD) (oromucosal route), THC (oromucosal route), and standardized dried cannabis (with THC; SCT; inhalation route) could reduce neuropathic pain score (SMD -0.41, 95% CI -0.7 to -0.1; -0.61, 95% CI -1.2 to -0.02; and -0.77, 95% CI -1.4 to -0.2; respectively). For nociceptive pain, only standardized cannabis extract (with THC; SCET) via oral route could reduce pain score (SMD -1.8, 95% C; -2.4 to -1.2). In cancer pain, THC/CBD via oromucosal route and THC via oral or oromucosal route could reduce pain score (SMD -0.7, 95% CI -1.2 to -0.2; and -2.1, 95% CI -2.8 to -1.4; respectively).
https://t.co/REclK6gdaC

Johal et al., Clin Med Insights Arthritis Musculoskelet Disord., 2020
Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis
Compared with placebo, cannabinoids showed a significant reduction in pain which was greatest with treatment duration of 2 to 8 weeks (weighted mean difference on a 0-10 pain visual analogue scale -0.68, 95% confidence interval [CI], -0.96 to -0.40, I 2 = 8%, P < .00001; n = 16 trials).
https://t.co/mHv2Aq9ZAN

Boland et al., BMJ Support Palliat Care., 2020
Cannabinoids for adult cancer-related pain: systematic review and meta-analysis
There was no difference between cannabinoids and placebo for the difference in the change in average Numeric Rating Scale pain scores (mean difference -0.21 (-0.48 to 0.07, p=0.14)); this remained when only phase III studies were meta-analysed: mean difference -0.02 (-0.21 to 0.16, p=0.80). Cannabinoids had a higher risk of adverse events when compared with placebo, especially somnolence (OR 2.69 (1.54 to 4.71), p<0.001) and dizziness (OR 1.58 (0.99 to 2.51), p=0.05). https://t.co/WZfZAOGybn

Yanes et al., Exp Clin Psychopharmacol., 2019
Effects of cannabinoid administration for pain: A meta-analysis and meta-regression
Results revealed that cannabinoid administration produced a medium-to-large effect across included studies, Cohen's d = -0.58, 95% confidence interval (CI) [-0.74, -0.43], while placebo administration produced a small-to-medium effect, Cohen's d = -0.39, 95% CI [-0.52, -0.26]. Meta-regression revealed that cannabinoids, β = -0.43, 95% CI [-0.62, -0.24], p < .05, synthetic cannabinoids, β = -0.39, 95% CI [-0.65, -0.14], p < .05, and sample size, β = 0.01, 95% CI [0.00, 0.01], p < .05, were associated with marked pain reduction.
https://t.co/VOhUK13u79

Stocking et al., PAIN, 2018
Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies
Across RCTs, pooled event rates (PERs) for 30% reduction in pain were 29.0% (cannabinoids) vs 25.9% (placebo); significant effect for cannabinoids was found; number needed to treat to benefit was 24 (95% confidence interval [CI] 15-61); for 50% reduction in pain, PERs were 18.2% vs 14.4%; no significant difference was observed. https://t.co/DIGTy2QQOt

Mücke et al., Cochrane., 2018
Cannabis-based medicines for chronic neuropathic pain in adults
Cannabis-based medicines may increase the number of people achieving 50% or greater pain relief compared with placebo (21% versus 17%; risk difference (RD) 0.05 (95% confidence interval (CI) 0.00 to 0.09); NNTB 20 (95% CI 11 to 100); 1001 participants, eight studies, low-quality evidence).
https://t.co/ms3dB0v8sN

Aviram et al., Pain Physician., 2017
Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
This analysis showed limited evidence showing more pain reduction in chronic pain -0.61 (-0.78 to -0.43, P < 0.0001), especially by inhalation -0.93 (-1.51 to -0.35, P = 0.001) compared to placebo. Moreover, even though this review consisted of some RCTs that showed a clinically significant improvement with a decrease of pain scores of 2 points or more, 30% or 50% or more, the majority of the studies did not show an effect. Consequently, although the primary analysis showed that the results were favorable to CBMs over placebo, the clinical significance of these findings is uncertain.
https://t.co/n2gvJnOGwg

Nugent et al., Ann Intern Med., 2017
The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms: A Systematic Review
From 27 chronic pain trials, there is low-strength evidence that cannabis alleviates neuropathic pain but insufficient evidence in other pain populations.
https://t.co/GNeEk7VsC2

Meng et al., Anesth Analg., 2017
Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis
Patients who received selective cannabinoids reported a significant, but clinically small, reduction in mean numerical rating scale pain scores (0-10 scale) compared with comparator groups (-0.65 points; 95% confidence interval, -1.06 to -0.23 points; P = .002, I = 60%; Grade of Recommendations Assessment, Development, and Evaluation: weak recommendation and moderate-quality evidence).
https://t.co/snbh1oSVKJ

McCormick et al., NASEM, 2017
The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research (2017)
There is substantial evidence that cannabis is an effective treatment for chronic pain in adults.
https://t.co/GNeEk7VsC2

Boyuchuk et al., J Oral Facial Pain Headache, 2015
The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review
Of the 24 studies that examined chronic neuropathic pain, 11 studies were excluded. The 13 included studies were rated using the Jadad Scale to measure bias in pain research. Evaluation of these studies suggested that cannabinoids may provide effective analgesia in chronic neuropathic pain conditions that are refractory to other treatments.
https://t.co/Ggf7wUABbL

Andrea et al., Jour of Pain., 2015
Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data
Our evidence synthesis of individual patient data from 178 participants with 405 observed responses in 5 randomized controlled trials following patients for days to weeks provides evidence that inhaled cannabis results in short-term reductions in chronic neuropathic pain for 1 in every 5 to 6 patients treated (number needed to treat = 5.6 with a Bayesian 95% credible interval ranging between 3.4 and 14).
https://t.co/vr825VfW9F

Whiting et al., JAMA, 2015
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Compared with placebo, cannabinoids were associated with a greater average number of patients showing a complete nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95% CI, 1.55-9.42]; 3 trials), reduction in pain (37% vs 31%; OR, 1.41 [95% CI, 0.99-2.00]; 8 trials), a greater average reduction in numerical rating scale pain assessment (on a 0-10-point scale; weighted mean difference [WMD], −0.46 [95% CI, −0.80 to −0.11]; 6 trials), and average reduction in the Ashworth spasticity scale (WMD, −0.12 [95% CI, −0.24 to 0.01]; 5 trials).
https://t.co/JYvodO0R9W

Martín-Sánchez et al., Pain Med, 2009
Systematic review and meta-analysis of cannabis treatment for chronic pain
The efficacy analysis (visual analog scales) displayed a difference in standardized means in favor of the cannabis arm of -0.61 (-0.84 to -0.37), with statistical homogeneity (I(2) = 0.0%; P = 0.50). For the analysis of harms, the following Odds Ratios (OR) and number needed to harm (NNH) were obtained: for events linked to alterations to perception, OR: 4.51 (3.05-6.66), NNH: 7 (6-9); for events affecting motor function, 3.93 (2.83-5.47), NNH: 5 (4-6); for events that altered cognitive function, 4.46 (2.37-8.37), NNH: 8 (6-12).
https://t.co/BC1ZFqBHwl

Iskedjian et al., Curr Med Res Opin., 2007
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
The cannabidiol/THC buccal spray decreased pain 1.7 +/- 0.7 points (p = 0.018), cannabidiol 1.5 +/- 0.7 (p = 0.044), dronabinol 1.5 +/- 0.6 (p = 0.013), and all cannabinoids pooled together 1.6 +/- 0.4 (p < 0.001). Placebo baseline-endpoint scores did not differ (0.8 +/- 0.4 points, p = 0.023). At endpoint, cannabinoids were superior to placebo by 0.8 +/- 0.3 points (p = 0.029). Dizziness was the most commonly observed adverse event in the cannabidiol/THC buccal spray arms (39 +/- 16%), across all cannabinoid treatments (32.5 +/- 16%) as well as in the placebo arms (10 +/- 4%).
https://t.co/5spOwbUf1t

[Meli Åkerman @Melikamisama]

Läs vår debattartikel från Patientföreningen MedCan!

@MedCanSe #MedCan #medicinskcannabis #cannabis

https://t.co/Ht1wNyHqfT

[MedCan.se @MedCanSe]

@MagasinKonkret Tack alla! Skriv under namninsamlingen:
https://t.co/Q4jPDDbKpI

[MedCan.se @MedCanSe]

Viktigt om TLV och högkostnadsskyddet!

[Sapphire Clinics @sapphireclinics]

Sapphire om TLV:s förslag: "Ett hot mot svårt sjuka patienters vård"

https://t.co/wbcO4thqKZ

[MedCan.se @MedCanSe]

Statens nya sparförslag: Ta ifrån sjuka deras medicin! 🧑‍🦽🆘🥦

[Magasinet Konkret @MagasinKonkret]

Tandvårds- och Läkemedelsförmånsverket vill utesluta runt 2 000 smärtpatienter från högkostnadsskyddet för medicinsk cannabis. Patientföreningen MedCan varnar för otrygg vård och ökad svart marknad. https://t.co/94SgRDIQKz

[MedCan.se @MedCanSe]

Trevlig midsommar! 😉

[MedCan.se @MedCanSe]

https://t.co/lB9IENgWD0

[MedCan.se @MedCanSe]

Vi vill lyfta två svenska podcasts som tar upp medicinskt bruk och patienternas perspektiv. https://t.co/RV1GrM4XGU

[MedCan.se @MedCanSe]

https://t.co/yrBFgTHSEu